Literature DB >> 30545564

Longitudinal Trends in the Diagnosis of Attention-Deficit/Hyperactivity Disorder and Stimulant Use in Preschool Children on Medicaid.

Deborah Winders Davis1, Yana Feygin2, Liza Creel3, P Gail Williams4, W David Lohr5, V Faye Jones6, Jennifer Le7, Natalie Pasquenza2, Soutik Ghosal8, Kahir Jawad2, Xiaofang Yan8, Gil Liu9, Samantha McKinley10.   

Abstract

OBJECTIVES: To describe trends in the diagnosis of attention-deficit/hyperactivity disorder (ADHD) and prescribing of stimulants in preschool-age children receiving Medicaid and to identify factors associated with the receipt of psychosocial care. STUDY
DESIGN: Data were extracted from 2012-2016 Kentucky Medicaid claims for children aged <6 years. ADHD was identified using International Classification of Diseases, Tenth Revision codes F90.0, F90.1, F90.2, F90.8, and F90.9. Psychosocial therapy was defined as having at least 1 relevant Current Procedural Terminology code in a claim within the year. A generalized linear model with a logit link and binomial distribution was used to assess factors associated with receipt of psychosocial treatment in 2016.
RESULTS: More than 2500 (1.24%) preschool-aged children receiving Medicaid had a diagnosis of ADHD in 2016, with 988 (38.2%) of those receiving a stimulant medication. Children in foster care were diagnosed with and/or treated for ADHD 4 times more often than other Medicaid recipients. Of the 1091 preschoolers receiving stimulants, 99 (9%) did not have a diagnosis of ADHD. There were no significant differences in diagnoses by race/ethnicity, but children reported to be black, Hispanic, or other race/ethnicity received stimulants at a lower rate than white children. Positive predictors for receiving psychosocial therapy in 2016 included having the diagnosis but not receiving a stimulant, having at least 1 prescription written by a psychiatrist, having comorbidities, and age. The use of stimulants in children aged <6 years declined from 0.9% in 2012 to 0.5% in 2016.
CONCLUSIONS: Promising trends demonstrate a decreasing use of stimulants in preschoolers; however, continued vigilance is needed to promote the optimal use of psychosocial interventions.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  attention-deficit/hyperactivity disorder; low income; preschool-age children; stimulants

Mesh:

Substances:

Year:  2018        PMID: 30545564     DOI: 10.1016/j.jpeds.2018.10.062

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  6 in total

1.  Disparities in ADHD Diagnosis and Treatment by Race/Ethnicity in Youth Receiving Kentucky Medicaid in 2017.

Authors:  Deborah Winders Davis; Kahir Jawad; Yana Feygin; Liza Creel; Maiying Kong; JingChao Sun; W David Lohr; P Gail Williams; Jennifer Le; V Faye Jones; Marie Trace; Natalie Pasquenza
Journal:  Ethn Dis       Date:  2021-01-21       Impact factor: 1.847

2.  Mental Health Surveillance Among Children - United States, 2013-2019.

Authors:  Rebecca H Bitsko; Angelika H Claussen; Jesse Lichstein; Lindsey I Black; Sherry Everett Jones; Melissa L Danielson; Jennifer M Hoenig; Shane P Davis Jack; Debra J Brody; Shiromani Gyawali; Matthew J Maenner; Margaret Warner; Kristin M Holland; Ruth Perou; Alex E Crosby; Stephen J Blumberg; Shelli Avenevoli; Jennifer W Kaminski; Reem M Ghandour
Journal:  MMWR Suppl       Date:  2022-02-25

3.  Rise, and pronounced regional variation, in methylphenidate, amphetamine, and lisdexamfetamine distribution in the United States.

Authors:  Sneha M Vaddadi; Nicholas J Czelatka; Belsy D Gutierrez; Bhumika C Maddineni; Kenneth L McCall; Brian J Piper
Journal:  PeerJ       Date:  2021-12-21       Impact factor: 2.984

4.  A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder.

Authors:  Ann C Childress; Eric Lloyd; Steven A Johnson; Lhanoo Gunawardhana; Valerie Arnold
Journal:  J Child Adolesc Psychopharmacol       Date:  2022-03-08       Impact factor: 2.576

5.  Anti-obesity medication prescriptions by race/ethnicity and use of an interpreter in a pediatric weight management clinic.

Authors:  Eric M Bomberg; Elise F Palzer; Kyle D Rudser; Aaron S Kelly; Carolyn T Bramante; Hilary K Seligman; Favour Noni; Claudia K Fox
Journal:  Ther Adv Endocrinol Metab       Date:  2022-04-11       Impact factor: 4.435

6.  Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder.

Authors:  Ann C Childress; Robert L Findling; James Wu; Scott H Kollins; Yi Wang; Patrick Martin; Brigitte Robertson
Journal:  J Child Adolesc Psychopharmacol       Date:  2020-02-11       Impact factor: 2.576

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.